Ardelyx Inc (ARDX)
ARDX · BiotechSign PipelinePipeline Overview
- Therapeutic Focus
- Nephrologysrc
Signal Snapshot
4
Clinical Trials (ClinicalTrials.gov aggregate)
0
Catalyst Records
5
Publications on Record
1 Phase 2, 3 Phase 3
Trial Phase Mix
ClinicalTrials.gov aggregate as of 2026-09-24. Source
Recent Publications
- Effect of Age and Age-Defined Menopausal Status on Linaclotide Efficacy and Safety in Adults With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation: Post Hoc Analyses of Phase 2b/3 Studies. — Neurogastroenterol Motil (2026) PMID 42702764
- Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis. — Circulation (2026) PMID 42610271
5 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for Ardelyx Inc.
Full ARDX Data Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.